Over 145 pages
of product analysis and forecasts
Unique market share and 5-year sales forecasts for leading products & prospects
A comprehensive examination of major gastrointestinal therapy areas
Critical competitive evaluation and scoring of current and up and coming products

Providing…

Detailed analysis and 5-year forecasts for current leading products by value
A detailed review and assessment of up and coming products
Unique product evaluation and scoring
An examination of the current understanding of IBD, IBS and GORD

Major approaches including
Tumour necrosis factor alpha inhibitors
Cell adhesion molecule inhibitors
T-cell modulators
Interleukin inhibitors
Serotonergic agents
H2 receptor antagonists
Proton pump inhibitors

THE REPORT COVERS MAJOR DISEASE AREAS
Inflammatory bowel disease (Crohn's disease & ulcerative colitis)
Irritable bowel syndrome
Gastro-oesophageal reflux disease (GORD)

THE FACTS
Risk factors, how the disease affects patients, diagnosis and stages of the disease

PATIENT STATISTICS
Prevalence in the US, Europe and Japan
Diagnosis rates

CURRENT TREATMENT OPTIONS
Interventions by type
Unique five point competitive assessment and scoring of current therapies and companies involved
Sales forecasts for key products to 2012

R&D: DRUGS IN PHASE II/III
Focus on new classes of drugs and the companies involved
Unique competitive assessment and scoring of new therapies and companies involved
5-year sales forecasts for key products from year of launch

EXTENSIVE TABLES AND CHARTS

Low levels of diagnosis and new biological approaches to treatment indicate a positive future for GI drugs. Even so, opportunities in a number of areas remain to be exploited

Inflammatory Bowel Disease
An estimated two million people in the US, Europe and Japan suffer from inflammatory bowel disease (IBD), a little over half of whom have ulcerative colitis and around 800,000 of whom have Crohn's disease. We expect the number of IBD patients around the world to increase to around 1.3 million people by 2012 and that the worldwide market for IBD to experience steady growth over the next five years. The main driving forces behind IBD market expansion will be the increased uptake of current and novel high-priced biological agents and growth of the diagnosed prevalent populations in the US and UK. These novel products will provide more treatment options for patients whose disease is unresponsive to less expensive, conventional IBD therapies (i.e., aminosalicylates, immunosuppressants, and corticosteroids). The availability of additional biologics will expand the percentage of IBD patients treated with these agents as an alternative biological agent is likely to be prescribed if the first one should fail.

Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) affects around 18% of the general population at some time. It is one of the most common disorders seen by physicians. The overall cost to the US healthcare system alone is around US$20-30 billion annually. A number of pharmaceutical companies believe that a safe and effective treatment for IBS could be worth up to US$4 billion. Despite this, there are very few therapies on the market aimed specifically at treating IBS. Patients' symptoms have traditionally been controlled by laxatives, anti-diarrhoeals, anticholinergics and antidepressants. More recently, two serotonergic agents have been released for this condition: GlaxoSmithKline's Lotronex (alosetron) and Novartis' Zelnorm (tegaserod), both of which have safety issues. The majority of IBS drugs currently in development aim to treat this disorder via novel mechanisms, the most promising of which are Sucampo Pharmaceuticals/Takeda's Amitiza (lubiprostone) and Microbia/Forest Laboratories' Linaclotide acetate. Both drugs act locally to increase fluid secretion into the gut. Amitiza has been filed for the treatment of constipation-predominant IBS, and Linaclotide acetate is in Phase II development for the same indication.

Gastro-oesophageal Reflux Disease
The combined market for H2 receptor antagonists and proton pump inhibitors, the two major GORD therapies currently in the marketplace, is estimated to be worth around US$25 billion. Sales of the leading branded PPIs, such as Nexium (esomeprazole), Prevacid (lansoprazole), and Prilosec (omeprazole) amounted to US$14.2 billion in 2006. However, currently available acid-suppression therapies are not adequately effective in all patients. New approaches are being pursued and are aimed at those patients who respond poorly or not at all to acid suppression therapy. One of these drugs is a promotility agent and three are aimed at tightening the lower oesophageal sphincter, thereby stopping the mechanism that results in GORD.
The products evaluated and forecast to 2012 include
ABT 874
AcipHex/Pariet
ADX10059
Amitiza
ATI-7505
Cimzia
DDP733
Golimumab
Humira
Losec/Prilosec
MLN0002
Nexium
Orencia
OX17
Pepcid/Glaster
Prevacid
Protonix
Remicade
STA 5326
Tysbari
XP19986
Zantac
Zelnorm

Questions answered
Will Novartis be able to overcome regulators' concerns with respect to its 5-HT4 agonist Zelnorm (tegaserod)?

What clinical advantages might Rottapharm's novel cholecystokinin (CCK-1) have in the IBS treatment market?

To what degree will Schering Plough/ Centocor's golimumab be affected if other anti-TNF products (Abbott's Humira and Celltech's Cimzia) reach the market first?